Abstract
Two hundred and eleven patients with node-positive stage II and III breast cancer were treated with eight cycles of adjuvant chemotherapy comprising cyclophosphamide, doxorubicin and oral ftorafur (CAFt), with and without tamoxifen. All patients had undergone radical surgery, and 148 patients were treated with post-operative radiotherapy in two randomized studies. The impact of haematological toxicity of CAFt on distant disease-free (DDFS) and overall survival (OS) was recorded. Dose intensity of all given cycles (DI), dose intensity of the two initial cycles (DI2) and total dose (TD) were calculated separately for all chemotherapy drugs and were correlated with DDFS and OS. Patients with a lower leucocyte nadir during the chemotherapy had significantly better DDFS and OS (P = 0.01 and 0.04 respectively). Dose intensity of the two first cycles also correlated significantly with DDFS (P = 0.05) in univariate but not in multivariate analysis, while the leucocyte nadir retained its prognostic value. These results indicate that the leucocyte nadir during the adjuvant chemotherapy is a biological marker of chemotherapy efficacy; this presents the possibility of establishing an optimal dose intensity for each patient. The initial dose intensity of adjuvant chemotherapy also seems to be important in assuring the optimal effect of adjuvant chemotherapy.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The maximum chemiluminescence intensity predicts severe neutropenia in gemcitabine-treated patients with pancreatic or biliary tract cancer
Cancer Chemotherapy and Pharmacology Open Access 14 September 2018
-
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer
Breast Cancer Research and Treatment Open Access 30 November 2017
-
Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring
Cancer Chemotherapy and Pharmacology Open Access 27 June 2017
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Saarto, T., Blomqvist, C., Rissanen, P. et al. Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 75, 301–305 (1997). https://doi.org/10.1038/bjc.1997.49
Issue Date:
DOI: https://doi.org/10.1038/bjc.1997.49
This article is cited by
-
Chemotherapy-induced neutropenia as a prognostic factor in patients with extensive-stage small cell lung cancer
European Journal of Clinical Pharmacology (2023)
-
Relevance of pharmacogenetic polymorphisms with response to docetaxel, cisplatin, and 5-fluorouracil chemotherapy in esophageal cancer
Investigational New Drugs (2022)
-
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer
Breast Cancer Research and Treatment (2018)
-
The maximum chemiluminescence intensity predicts severe neutropenia in gemcitabine-treated patients with pancreatic or biliary tract cancer
Cancer Chemotherapy and Pharmacology (2018)
-
Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring
Cancer Chemotherapy and Pharmacology (2017)